Navigation Links
Stem Cell Transplant May Help Aggressive MS: Study
Date:3/21/2011

By Amanda Gardner
HealthDay Reporter

MONDAY, March 21 (HealthDay News) -- Stem cell transplants may hold some hope for patients with rapidly progressing multiple sclerosis, the authors of a long-term study report.

The controversial treatment, known as hematopoietic stem cell transplantation (HSCT), involves ablating, or removing, the patients' immune and other blood cells, then replacing it with new bone marrow stem cells from the same patient.

The idea is to "reset the thermostat and start fresh," said Dr. Aaron Miller, chief medical officer for the National Multiple Sclerosis Society and a professor of neurology at Mount Sinai School of Medicine in New York City.

But Miller, who was not involved in the study, doubts the procedure will become a viable option for patients with aggressive multiple sclerosis.

"This is a very heroic form of therapy for multiple sclerosis [MS], which is unlikely, in my view, ever to have a major impact on the field," added Miller. "It's a substantially risky therapy -- the mortality rates have been in the 2-3 percent range . . . and it's hugely expensive."

MS is a disease of the nervous system. There is no known cause or cure, and in severe cases patients may be unable to write, speak or walk.

This study, published in the March 22 issue of Neurology, was begun 15 years ago. Back then, "perhaps we didn't have other good alternatives for aggressive disease," he said. "I think we now have better and safer alternatives."

Those alternatives include the biologic therapies Tysabri (natalizumab) and Gilenya (fingolimod), approved in 2006 and 2010, respectively. But Miller emphasized these can only be considered "potentially" more effective than HSCT because the two have never been tested head-to-head.

The trial organizers reported earlier that 80 percent of patients receiving HSCT treatment had stabilized disease after five years. They also noted positive brain changes on an MRI.

Now, after 15 years, the authors report that overall 25 percent of the 35 initial patients are stabilized. The success rate was better -- 44 percent -- for those with active brain lesions, signaling aggressive disease, they found.

Many had a lessening of their disability, and fewer and smaller lesions in the brain.

But two participants, or 6 percent, died of complications from the transplant.

Research on this aggressive therapy is continuing, say the authors, from Aristotle University of Thessaloniki Medical School in Greece.

But more information might be hard to come by because the treatment's high mortality rate makes it difficult to recruit patients.

Still, they said, HSCT might be a "salvage" therapy for hard-to-treat MS.

"It's a possible treatment strategy, but it remains to be seen how much of a treatment option it is," said Dr. Mark Keegan, associate professor of neurology at the Mayo Clinic in Rochester, Minn.

"We do need ways to treat people with aggressive MS," he added.

More information

Visit the National Multiple Sclerosis Society for more on this disease.

SOURCES: Aaron Miller, M.D., chief medical officer, National Multiple Sclerosis Society, and associate professor of neurology and director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York City; Mark Keegan, M.D., associate professor of neurology, Mayo Clinic, Rochester, Minn.; March 22, 2011 Neurology


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Survival matching should be used to allocate donated kidneys to transplant recipients
2. Transplant Drug May Fight Rare Lung Disorder
3. Alcohol abuse history influences quality of life following liver transplant
4. Transplanting umbilical cord and menstrual blood-derived stem cells offer hope for disorders
5. White Patients Most Likely to Get Kidney Transplants: Study
6. Kidney Transplant Patients Urged to Keep Fit to Survive
7. Study Rates Success of Corneal Transplants in Kids
8. Redesign of US donor-liver network could boost transplants by several hundred per year
9. Researchers work at the frontiers of islet cell transplantation
10. Gene protects lung from damage due to pneumonia, sepsis, trauma, transplants
11. Transplanted human placenta-derived stem cells show therapeutic potential in stroke models
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stem Cell Transplant May Help  Aggressive MS: Study 
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... ... Film Studios. With inMotion3D Abstract users can distort and manipulate three-dimensional shapes with ... position, rotation, columns, rows, ranks, point, lines, polygons, polygon texture animation, opacity texture ...
(Date:4/30/2016)... , ... April 30, 2016 ... ... CBC News on April 4th, 2016 questioned the use of the HyProCure ... EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, ...
(Date:4/29/2016)... ... 29, 2016 , ... In an article published April 16th on ... Botox and lip injections, which she underwent in order to feel more at home ... Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic ...
(Date:4/29/2016)... ... 29, 2016 , ... On Tuesday, April 26, 2016 members of the HomeTown ... of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , ... 70% tax credit to individuals and corporations which donate directly to a “rural hospital” ...
(Date:4/29/2016)... Stewart, GA (PRWEB) , ... April 29, 2016 , ... ... Monday, May 16, 2016, at its new location in the Exchange Furniture Mall at ... a raffle for a 50-inch Samsung Smart TV. Plus attendees will have the opportunity ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , Net Sales of $1.90 billion represent ... prior year period, and an increase of 1.2% on an ... for the first quarter were $0.52 reported, a decrease of ... increase of 29.9% over the prior year period , ... for 2016 Zimmer Biomet Holdings, Inc. (NYSE and ...
(Date:4/28/2016)... Calif. , April 28, 2016 /PRNewswire/ ... Validation Lifecycle Management Solutions (VLMS) today announced ... and services for sufferers of chronic kidney ... System to manage their corporate validation process. ... seeking a software solution to manage their ...
(Date:4/27/2016)... April 27, 2016 ... Forums in Zürich gab Strekin AG den ... STR001 zur Erhaltung des Resthörvermögens von Patienten, ... Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden ... STR001 wird während der Operation direkt ins ...
Breaking Medicine Technology: